ZM-241,385
ZM-241,385
|
|
IUPAC ime
|
|
4-(2-(7-amino-2-(furan-2-il)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ilamino)etil)fenol |
|
Identifikacija
|
CAS registarski broj
|
139180-30-6 Y
|
PubChem[1][2]
|
176407
|
ChemSpider[3]
|
153646 Y
|
ChEMBL[4]
|
CHEMBL1628689 Y
|
IUPHAR ligand
|
405
|
Jmol-3D slike
|
Slika 1
|
|
Oc1ccc(CCNc2nc3nc(c4ccco4)nn3c(N)n2)cc1 |
|
|
InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22) N Kod: PWTBZOIUWZOPFT-UHFFFAOYSA-N N
InChI=1/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22) Kod: PWTBZOIUWZOPFT-UHFFFAOYAJ |
|
Svojstva
|
Molekulska formula
|
C16H15N7O2
|
Molarna masa
|
337.34 g mol−1
|
Y (šta je ovo?)
(verifikuj)
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
|
Infobox references
|
ZM-241,385 je antagonist visokog afiniteta koji je selektivan za adenosinski A2A receptor.[5]
U životinjskim modelima je pokazano da ZM-241,385 pruža zaštitu protiv beta amiloidne neurotoksičnosti i da stoga može da bude koristan u tretmanu Alchajmerove bolesti.[6] ZM-241,385 isto tako povećava otpuštanje dopamina izvedenog iz L-DOPA i stoga je koristan u tretmanu Parkinsonove bolesti.[7]
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Palmer TM, Poucher SM, Jacobson KA, Stiles GL (December 1995). „125I-4-(2-(7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5) triazin-5-yl-amino)ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor”. Molecular Pharmacology 48 (6): 970-4. PMID 8848012. Arhivirano iz originala na datum 2008-09-07. Pristupljeno 2014-04-11.
- ↑ Dall'Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR, Dall'lgna OP (April 2003). „Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity”. British Journal of Pharmacology 138 (7): 1207-9. DOI:10.1038/sj.bjp.0705185. PMC 1573785. PMID 12711619.
- ↑ Gołembiowska K, Dziubina A (September 2004). „Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats”. Neuropharmacology 47 (3): 414-26. DOI:10.1016/j.neuropharm.2004.04.018. PMID 15275831.
Vanjske veze
MeSH ZM+241385
|
|